AUS
NZ
UK
CA
USA
IND
Highlights
- Chimeric is set to present the ADVENT-AML Phase 1B clinical trial at the ASH.
- The abstract will highlight the clinical trial design and objective.
- The clinical trial will examine CHM 0201 along with standard of care for AML patients.
Chimeric Therapeutics Limited (ASX: CHM) informed that the abstract of ADVENT-AML Phase 1B clinical trial has been accepted for presentation by the American Society of Haematology (ASH). The abstract will be presented at the 2023 annual meeting of ASH, scheduled on 9-12 December 2023 in San Diego, California.
The abstract highlights the design and objective of the ADVENT-AML clinical trial. CHM informed that ADVENT-AML clinical trial is the first trial to assess the synergy of CHM 0201 NK cells with the standard of care of Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) patients.
Data source: Company update
More on CHM 0201
In 2022, CHM 0201 saw positive Phase 1A clinical data. CHM 0201 is the NK cell platform of CHM.
The Phase 1A clinical trial demonstrated the safety, persistence and expansion of CHM 0201 cells along with the promising efficacy in solid tumours and blood cancers.
One of the most significant results of the trial was the achievement of a complete response to CHM 20201 in one AML patient, and this has remained in ongoing complete remission for over two years to date.
About ADVENT-AML clinical trial
Data source: Company update
The study has obtained FDA IND approval and clearance from MDACC IRB.
The trial is designed to register up to 20 patients with newly diagnosed AML and who are not eligible for intensive chemotherapy or allogenic stem cell transplant. The enrolment for the trial is anticipated to begin by the end of 2023.
CHM shares traded at AU$0.032, up over 6%, in the early hours of trade on 22 November 2023.
